Clinical trials: Version
Melanoma, Child
Family Lifestyles, Actions, and Risk Education Intervention: Version 2
The overall purpose of this study is to determine the efficacy of the Family Lifestyles, Actions, and Risk Education (FLARE) intervention in improving melanoma preventive behaviors.
- Trial name
- FLARE (NCT04201223)
- Testing
- FLARE Intervention
- Where
- United States
- Volunteers
- 752 people, healthy volunteers welcome
- Sponsor
- University of Utah
ADHD
Adult Normative Performance of the Quotient ADHD System
This study is being conducted to enhance and extend the clinical utility of the Quotient® ADHD System Adolescent and Adult Version Test by adding large numbers of well-screened controls to the existing Quotient® ADHD System…
- Trial name
- ADHD (NCT01308450)
- Where
- United States
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- BioBehavioral Diagnostics Company
Adverse Childhood Experiences, Domestic Violence
The Impact of an Adapted Version of the Strengthening Families Program on IPV Among Caregivers and ACEs Among Children
Adverse childhood experiences (ACEs) are unfortunately common and the known outcomes are concerning. However, very little is currently known about programs that may prevent ACEs among children, such as witnessing intimate partner…
- Trial name
- NCT05129501
- Testing
- Experimental
- Where
- United States
- Volunteers
- 318 people, healthy volunteers welcome
- Sponsor
- University of Nebraska Lincoln
HIV Infections
Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries
The purpose of this study was to examine, in an integrated and comprehensive fashion, three critical questions currently facing HIV-infected pregnant and postpartum women and their infants: 1.
- Trial name
- PROMISE (NCT01061151)
- Testing
- Zidovudine (ZDV), Nevirapine (NVP): Antepartum Mothers, Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail
- Where
- 14 sites in India, Malawi and 5 more
- Volunteers
- 3,747 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)